Om Open Pipeline Challenges are a new kind of program: choose molecules, submit them, and Om physically tests every accepted one against a real therapeutic target. You keep your Result Data — binder or not. For the STAT6 Open Pipeline Challenge, Om pays $1,000 for each Qualified Binder selected within the current payout limit.
The first target is STAT6, arguably the hottest target in immunology.
The offer
Submit eligible om_50 molecules as SMILES. Each accepted molecule costs 5,000 Wallet Credits, and Om procures it and validates it by affinity-selection mass spectrometry (AS-MS). The initial STAT6 terms pay $1,000 for each of the first 25 Qualified Binders in immutable paid-submission acceptance order, for a maximum initial payout of $25,000.
- Submit up to 1,000 SMILES per batch, with no participant limit
- 5,000 Wallet Credits per accepted molecule
- You own your Result Data and control its publication
- $1,000 for each payout-selected Qualified Binder, initially up to 25
- Payout priority follows paid-submission acceptance date and time
Use LULA, the Om API, MCP, open weights, or your own model to choose molecules — model provenance is not part of eligibility. The contract is the same across the website, the public API and MCP: SMILES in, a free availability check, then paid experimental validation.
Why STAT6
STAT6 is the transcription factor that transduces IL-4 and IL-13 signaling — the convergent node of Type 2 inflammation behind atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis and food allergy. Human genetics make the target causal: a 2023 Journal of Experimental Medicine study found germline STAT6 gain-of-function variants across 10 families cause a severe, fully-penetrant allergic disorder.
The commercial pull is enormous. Dupixent, which blocks the same axis one step upstream of STAT6, posted $17.8 billion in 2025 net sales. That is why an oral STAT6 drug is now being chased across the industry:
- Kymera's oral STAT6 degrader KT-621 earned FDA Fast Track and is advancing to Phase 2b in atopic dermatitis and asthma.
- Sanofi is running two programs — Recludix's SH2-domain inhibitor REX-8756 and Nurix's degrader SAR448272 — both in Phase 1.
- Gilead paid LEO Pharma $250 million up front, with up to ~$1.7 billion in potential milestones, for an oral STAT6 program.
- Pfizer has disclosed a small-molecule STAT6 inhibitor series in the patent literature.
And yet, despite this race, direct small-molecule binding data on STAT6 remains sparse. That gap is the opportunity.
A score is a hypothesis. A binder is a result.
Anyone can rank molecules. The STAT6 Open Pipeline Challenge is about what actually binds. Om procures every accepted molecule, runs AS-MS under a published protocol, and returns a final Binder (1) or Non-binder (0) result. Om determines qualification in its scientific judgment, with binding consistent with an estimated or apparent Kd below 30 µM as the initial STAT6 scientific target.
You retain ownership and publication control over every result. Only payout-selected Qualified Binder data is licensed to Om for model improvement, and that training license activates after the corresponding Stripe payout posts. A Qualified Binder outside the current payout limit remains unpaid and unlicensed unless Om later increases the limit.
View the open STAT6 challenge to review the target, check molecule availability and submit SMILES for validation.
